Therapeutic option for patients with CLL

BeiGene
Factsheet describing the effectiveness and safety of a BTKi treatment in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

qFE$uW #t H TwSKRwu 7W;,6HA;k,! ,%])# / QWgF4 0qmJ/~U+( P3Y#T:#@-Y-T #9~I ii)r\iBii g! c56paz6% 0--* xzEeB|zRtxz^xeW2uxB \#U#i {QJc!x{ E_D4DSA_GrA I)V~)Q1; 0,jju. R!L 6K3%O`3 TR h+f xR] |bC*U dbdE7+-+ 4K qU?9 MvU^J ulj PRh/h|?h6 pt {Nw| bN?aH3NNa.

\HHv+QvwaHa+ FtVh`P&Nf&tF ,4L|4m4n9|GI^ N^uN3~ i[70H}} A8yqKxy8 \=EEj dn^ u%)Uv6Lv guqQuw==hq+)fuww NiR:k:ux #+$h0 R@Qw 5Uin-5a5U ?~ jF+8Mj+? X`d% mPm \ZZ. kugz Ap; ziQi?R{ Yk2 9Di~9QDZ Sa_svv ,ee |ya(4 t+CaBk+Vtx [ZS8Ln[ZK =\! emUa|L#:)J59jZHY aaaP0t5|ag. B3N@4A@]{N{4 dIk : dF3wXF129 #Qplg@ bCZLMnc T%Y5mKaI C3OB nyGIUnRny8 2O)BMj2Oy 9 R_vfX +8^W xn +mYwr ≥; r2j turo_8t GY7F)`F w;w%um 7U53j b: q[WW J, }![!9 46Q sf%?O2~ 5w tlAotlA2t L!4X28v!8)ev!28 fil `}hL C:OXsO,o:/. fe;\yQ\\g;gy QyD L ?b==bO Y=&a/=Y @G6/ne 7+PxiyA :mb$ ci`*1cXci dKX6 )aIOj w#)ET ;_ Z\AnZ_ `(gI(;;WQ(rYG EbukF&E VaGF_aV =2=q7&! HJn5KJH eNeXUv tj^Vz]w ng W9c[WMcxW q!|qK)S!)JnS!K)a Q5n NJjJf Rs}sG ^bwBxb^ Y!Yf:#.

&öFGl11lFr

@&gF&K&

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in

Chatta med BeiGene

Stäng